CHRS News and Press, Coherus BioSciences Inc. From 01/23/26

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.0% to $2.0582 on volume of 396,224,419 shares Intel Corporation (INTC) fell 17.7% to $44.73 on volume of 245,750,101 shares SCWorx Corp. (WORX) rose 37.3% to $0.2501 on volume of...

2026-01-23 13:24:02 ET More on Coherus Oncology Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Coherus Oncology: A Two-Pronged March With Mid-2026 Implications Coherus Oncology, Inc. (CHRS) Presents at UBS Global He...

2026-01-22 16:15:04 ET Oppenheimer analyst issues OUTPERFORM recommendation for CHRS on January 22, 2026 09:08PM ET. CHRS was trading at $1.59 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 13 - Buy, 3 -...

Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape Canada NewsWire Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC , Jan. 16, 2026 /CNW/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a structural re...

2026-01-13 16:16:02 ET Coherus Oncology, Inc. (CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST... Read the full article on Seeking Alpha For further details see: Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Con...

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff [1] . This massive pressure is forcing a ...

REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session wil...

ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company’s Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate fi...

-Coherus Oncology formally introduces non-proprietary name:  tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies- -Data show CCR8 target is present with high prevalence and density in many ...

2025-12-23 11:06:46 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: Coherus Oncology: A Two-Pronged March With Mid-2026 Implications